<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996359</url>
  </required_header>
  <id_info>
    <org_study_id>020901</org_study_id>
    <secondary_id>P30CA072720</secondary_id>
    <secondary_id>CDR0000656757</secondary_id>
    <secondary_id>IRB# 0220090213</secondary_id>
    <nct_id>NCT00996359</nct_id>
  </id_info>
  <brief_title>Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation</brief_title>
  <official_title>Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low-dose total-body irradiation before a donor stem cell transplant helps&#xD;
      stop the growth of cancer cells. It also stops the patient's immune system from rejecting the&#xD;
      donor's stem cells. The donated stem cells may replace the patient's immune cells and help&#xD;
      destroy any remaining cancer cells (graft-versus-tumor effect).&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects of donor stem cell transplant after&#xD;
      total-body irradiation and to see how well it works in treating patients with relapsed or&#xD;
      refractory hematologic cancer or acute myeloid leukemia or acute lymphocytic leukemia in&#xD;
      complete remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the toxicity of irradiated haploidentical allogeneic cellular therapy after&#xD;
           low-dose total-body irradiation and no pharmacologic graft-vs-host disease prophylaxis&#xD;
           in patients with relapsed or refractory hematologic malignancies or patients with acute&#xD;
           myeloid leukemia (AML) or acute lymphoblastic leukemia in second or greater complete&#xD;
           remission (CR2).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate immunologic parameters before and after haploidentical therapy.&#xD;
&#xD;
        -  To demonstrate host anti-leukemia T-cells in a subset of patients with AML who are&#xD;
           HLA-A2-positive.&#xD;
&#xD;
        -  To observe any evidence of antitumor activity within the confines of this pilot study&#xD;
           and/or assess the duration of remission in those patients who enter the study in CR2.&#xD;
&#xD;
      OUTLINE: Patients undergo low-dose total-body irradiation and infusion of irradiated donor&#xD;
      cells on day 0. Patients also receive filgrastim subcutaneously (SC) daily or pegfilgrastim&#xD;
      SC every 14 days starting on day 1.&#xD;
&#xD;
      Patients in complete remission (CR) or with persistent disease undergo irradiated donor&#xD;
      lymphocyte infusion (DLI) at 8 weeks. Repeat irradiated DLI is administered if patients&#xD;
      remain in CR or achieve stable or responding disease after the second infusion (if confirmed&#xD;
      by histologic assessment) or third infusion (if confirmed by radiographic assessment). DLI&#xD;
      repeats every 8 weeks pending disease and clinical status up to a total of 6 infusions over a&#xD;
      12-month period.&#xD;
&#xD;
      Blood samples are collected at baseline, upon recovery of counts, and then monthly thereafter&#xD;
      for immunologic studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed up periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual&#xD;
  </why_stopped>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunologic parameters before and after haploidentical therapy</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity and/or duration of remission in those patients who enter the study in second complete remission or greater</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related mortality</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Irradiated allogeneic lymphocytes after Total Body Irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Irradiated haploidentical allogeneic lymphocytes</intervention_name>
    <description>Partially HLA-matched irradiated donor lymphocytes will be infused after total body irradiation.</description>
    <arm_group_label>Irradiated allogeneic lymphocytes after Total Body Irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>100 cGy TBI</description>
    <arm_group_label>Irradiated allogeneic lymphocytes after Total Body Irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Patients over 18 years old must meet the following criteria:&#xD;
&#xD;
               -  Histologically confirmed hematologic malignancy and not a candidate for a&#xD;
                  standard allogeneic transplantation&#xD;
&#xD;
               -  High-risk disease, including:&#xD;
&#xD;
                    -  Refractory/relapsed acute myeloid leukemia (AML) or AML in second or greater&#xD;
                       completion remission (CR2)&#xD;
&#xD;
                    -  Relapsed or refractory acute lymphoblastic leukemia (ALL) or ALL in CR2&#xD;
&#xD;
                    -  Tyrosine kinase inhibitor-resistant chronic myelogenous leukemia in chronic,&#xD;
                       accelerated, or blast crisis&#xD;
&#xD;
                    -  Fludarabine-resistant chronic lymphocytic leukemia&#xD;
&#xD;
                    -  High-risk myelodysplastic syndrome (MDS) (i.e., MDS with a score ≥ 1.5 by&#xD;
                       the International Scoring System)&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia&#xD;
&#xD;
                    -  Relapsed diffuse large cell non-Hodgkin lymphoma (NHL) with measurable&#xD;
                       disease after (or not eligible for) high-dose chemotherapy/autologous&#xD;
                       hematopoietic stem cell (HSC) rescue or allogeneic hematopoietic stem cell&#xD;
                       transplantation (HSCT)&#xD;
&#xD;
                    -  Relapsed follicular NHL, mantle cell lymphoma, or low-grade histology NHL&#xD;
                       with measurable disease after (or not eligible for) high-dose&#xD;
                       chemotherapy/autologous HSC rescue or allogeneic HSCT&#xD;
&#xD;
                    -  Relapsed or refractory high-grade/aggressive NHL (Burkitt lymphoma,&#xD;
                       lymphoblastic lymphoma, T-cell lymphoma, NK-like lymphoma) with measurable&#xD;
                       disease after (or not eligible for) high-dose chemotherapy/autologous HSC&#xD;
                       rescue or allogeneic HSCT&#xD;
&#xD;
                    -  Hodgkin lymphoma with measurable disease after (or not eligible for)&#xD;
                       high-dose chemotherapy/autologous HSC rescue or allogeneic HSCT&#xD;
&#xD;
                    -  Relapsed or refractory multiple myeloma after (or not eligible for)&#xD;
                       high-dose chemotherapy/autologous HSC rescue and following salvage therapy&#xD;
                       with thalidomide, lenalidomide, bortezomib or other FDA-approved multiple&#xD;
                       myeloma salvage therapies&#xD;
&#xD;
          -  Patients 13-17 years old must meet the following criteria:&#xD;
&#xD;
               -  Histologically confirmed hematologic malignancy and not a candidate for a&#xD;
                  standard allogeneic transplantation&#xD;
&#xD;
               -  High-risk disease, including:&#xD;
&#xD;
                    -  Refractory/relapsed AML or AML in CR2&#xD;
&#xD;
                    -  Relapsed or refractory ALL or ALL in CR2&#xD;
&#xD;
                    -  Relapsed diffuse large cell NHL with measurable disease after (or not&#xD;
                       eligible for) high-dose chemotherapy/autologous HSC rescue or allogeneic&#xD;
                       HSCT&#xD;
&#xD;
                    -  Relapsed follicular NHL, mantle cell lymphoma (or low-grade histology NHL)&#xD;
                       with measurable disease after (or not eligible for) high-dose&#xD;
                       chemotherapy/autologous HSC rescue or allogeneic HSCT&#xD;
&#xD;
                    -  Relapsed or refractory high-grade/aggressive NHL (Burkitt lymphoma,&#xD;
                       lymphoblastic lymphoma, T-cell lymphoma, NK-like lymphoma) with measurable&#xD;
                       disease after (or not eligible for) high-dose chemotherapy/autologous HSC&#xD;
                       rescue or allogeneic HSCT&#xD;
&#xD;
                    -  Hodgkin lymphoma with measurable disease after (or not eligible for)&#xD;
                       high-dose chemotherapy/autologous HSC rescue or allogeneic HSCT&#xD;
&#xD;
          -  Eligible for haploidentical irradiated cellular therapy&#xD;
&#xD;
          -  No known active brain metastases or malignant meningitis&#xD;
&#xD;
          -  Available partially (≥ 3/6 class I antigen) HLA-matched (by serology) related donor&#xD;
             NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by&#xD;
             PDQ. The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former&#xD;
             terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol&#xD;
             uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2&#xD;
&#xD;
          -  Karnofsky PS 60-100% (for patients &gt; 16 years) or Lansky PS 60-100% (for patients ≤ 16&#xD;
             years)&#xD;
&#xD;
               -  Patients who are unable to walk because of paralysis but who are up in a&#xD;
                  wheelchair will be considered ambulatory for the purpose of assessing PS&#xD;
&#xD;
          -  Patients ≥ 18 years:&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 times upper limit of normal (ULN) (unless attributable to&#xD;
                  Gilbert disease)&#xD;
&#xD;
               -  DLCO/alveolar volume &gt; 50%&#xD;
&#xD;
               -  Serum creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Patients 13-17 years:&#xD;
&#xD;
               -  Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR serum creatinine based on&#xD;
                  age/gender as follows:&#xD;
&#xD;
                    -  13 to &lt; 16 years: 1.5 mg/dL (male) or 1.4 mg/dL (female)&#xD;
&#xD;
                    -  ≥ 16 years: 1.7 mg/dL (male) or 1.4 mg/dL (female)&#xD;
&#xD;
               -  AST/ALT ≤ 2.5 times ULN for age&#xD;
&#xD;
               -  Total bilirubin &lt; 2.0 mg/dL (unless attributable to Gilbert syndrome)&#xD;
&#xD;
               -  Shortening fraction ≥ 27% by ECHO or ejection fraction ≥ 50% by radionuclide&#xD;
                  angiogram&#xD;
&#xD;
               -  FEV_1, forced vital capacity, and DLCO corrected for hemoglobin ≥ 60% by&#xD;
                  pulmonary function tests (PFTs)&#xD;
&#xD;
                    -  Children unable to cooperate for PFTs must meet the following criteria:&#xD;
&#xD;
                         -  No evidence of dyspnea at rest&#xD;
&#xD;
                         -  No exercise intolerance&#xD;
&#xD;
                         -  No requirement for supplemental oxygen therapy&#xD;
&#xD;
               -  Any other organ dysfunction thought to be secondary to disease will be considered&#xD;
                  separately and the patient will be eligible at the physician's discretion&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception before, during, and for 24 weeks&#xD;
             after study treatment&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No history of current or prior medical problems that, in the investigator's opinion,&#xD;
             would prevent administration of study treatment or assessment of response due to&#xD;
             excess toxicity&#xD;
&#xD;
          -  No active uncontrolled infections or other medical, psychological, or social&#xD;
             conditions that might increase the likelihood of patient adverse effects or poor&#xD;
             outcomes&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No corticosteroids within 2 weeks before receiving irradiated donor lymphocyte&#xD;
             infusion&#xD;
&#xD;
          -  No medications that might increase the likelihood of patient adverse effects or poor&#xD;
             outcomes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Strair, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>October 15, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <last_update_submitted>September 13, 2013</last_update_submitted>
  <last_update_submitted_qc>September 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>peripheral T-cell lymphoma</keyword>
  <keyword>hepatosplenic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

